Skip to main content
Terug
Watch Compare

Vivos Therapeutics, Inc.

Datakwaliteit: 100%
VVOS
Nasdaq Manufacturing Measuring & Analyzing Instruments
€ 1,21
▲ € 0,05 (4,31%)
Marktkapitalisatie: 13,59 M
Prijs
€ 1,15
Marktkapitalisatie
13,59 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Revenue grew 3,56% annually over 5 years — modest growth
Debt/Equity of 3,31 — high leverage
Negative free cash flow of -15,37 M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 5,35%
Capital efficient — spends only 5,63% of revenue on capex

Groei

Revenue Growth (5Y)
3,56%
Boven sectorgemiddelde (1,82%)
Revenue (1Y)8,91%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-480,76%
Onder sectorgemiddelde (-53,34%)
ROIC-68,18%
Net Margin-98,76%
Op. Margin-94,23%

Veiligheid

Debt / Equity
3,31
Boven sectorgemiddelde (0,31)
Current Ratio0,78
Interest CoverageN/A

Waardering

PE (TTM)
-0,79
Boven sectorgemiddelde (-1,47)
P/B Ratio5,37
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E -0,8 -1,5
P/B 5,4 1,6
ROE % -480,8 -53,3
Net Margin % -98,8 -41,5
Rev Growth 5Y % 3,6 1,8
D/E 3,3 0,3

All Fundamental Metrics
Growth
Revenue Growth (1Y) 8,91% Revenue Growth (3Y) -3,15%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 3,56% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 17,32 M Net Income (TTM) -17,10 M
ROE -480,76% ROA -66,19%
Gross Margin 55,73% Operating Margin -94,23%
Net Margin -98,76% Free Cash Flow (TTM) -15,37 M
ROIC -68,18% FCF Growth (3Y) N/A
Safety
Debt / Equity 3,31 Current Ratio 0,78
Interest Coverage N/A Asset Turnover 0,67
Working Capital -1,65 M Tangible Book Value -8,09 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0,79 Forward P/E N/A
P/B Ratio 5,37 P/S Ratio 0,79
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -113,03%
Market Cap 13,59 M Enterprise Value 18,89 M
Per Share
EPS (Diluted TTM) -1,77 Revenue / Share 1,46
FCF / Share -1,30 OCF / Share -1,22
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 5,63% FCF Conversion 89,84%
SBC-Adj. FCF -16,12 M Growth Momentum 5,35

Income Statement

Annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue 15,03 M 13,80 M 16,02 M 16,89 M 13,07 M
Net Income -11,14 M -13,58 M -23,85 M -20,29 M -12,06 M
EPS (Diluted) -2,22 -11,14 — — —
Gross Profit 9,02 M 8,27 M 10,02 M 12,60 M 10,41 M
Operating Income -11,17 M -17,30 M -25,03 M -20,38 M -12,04 M
EBITDA — — — — —
R&D Expenses 100.000,0 100.000,0 200.000,0 — —
SG&A Expenses — — — — —
D&A 581.000,0 621.000,0 669.000,0 733.000,0 717.865,0
Interest Expense — — 14.000,0 14.000,0 96.681,0
Income Tax — — — — —

Balance Sheet

Annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 15,28 M 10,73 M 13,72 M 33,69 M 25,33 M
Total Liabilities 7,33 M 10,32 M 8,92 M 8,15 M 8,41 M
Shareholders' Equity 7,95 M 411.000,0 4,80 M 25,54 M 16,92 M
Total Debt — — — 1,27 M 1,29 M
Cash & Equivalents 6,26 M 1,64 M 3,52 M 24,03 M 18,21 M
Current Assets 7,47 M 2,46 M 5,42 M 27,32 M 20,39 M
Current Liabilities 4,98 M 7,29 M 6,81 M 7,51 M 7,82 M